Bal Pharma Limited (BOM:524824)

Bal Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	72.1	17.52	41.96	14.87	11.13
Short-Term Investments	20.82	86.59	157.33	59.76	47.3
Cash & Short-Term Investments	92.92	104.1	199.29	74.63	58.43
Cash Growth	-10.74%	-47.76%	167.05%	27.72%	47.14%
Accounts Receivable	936.33	924.44	996.22	939.76	753.12
Other Receivables	-	31.07	32.81	27.56	51.87
Receivables	947.98	966.83	1,043	976.92	828.67
Inventory	1,164	1,030	878.11	980.05	743.96
Prepaid Expenses	-	13.44	9.69	7.2	5.86
Other Current Assets	417.88	234.13	211.66	242.77	208.79
Total Current Assets	2,622	2,349	2,342	2,282	1,846
Property, Plant & Equipment	841.76	737.76	647.89	621.79	571.85
Long-Term Investments	-	42.35	2.81	13.98	18.09
Goodwill	38.27	38.27	38.27	38.29	38.29
Other Intangible Assets	134.22	9.79	12.49	13.16	2.09
Long-Term Deferred Tax Assets	8.04	4.1	-	21.67	-
Long-Term Deferred Charges	-	110.18	101.32	91.41	77.83
Other Long-Term Assets	110.77	65.73	52.82	48.9	47.53
Total Assets	3,755	3,357	3,198	3,132	2,605

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	889.68	816.86	774.64	789.23	655.64
Accrued Expenses	7.76	73.14	37.77	34.69	70.82
Short-Term Debt	-	1,073	957.61	927.17	707.49
Current Portion of Long-Term Debt	1,276	116.7	74.88	77.6	58.79
Current Portion of Leases	-	6.38	12.77	8.55	7.62
Current Income Taxes Payable	-	-	22.18	60.06	43.93
Other Current Liabilities	318.52	108.83	150.72	196.06	112.17
Total Current Liabilities	2,492	2,195	2,031	2,093	1,656
Long-Term Debt	318.85	314	363.49	305.23	270.14
Long-Term Leases	-	12.9	13.74	12.25	22.54
Pension & Post-Retirement Benefits	-	47.32	42.62	42.38	39.82
Long-Term Deferred Tax Liabilities	-	-	15.49	28.69	6.04
Other Long-Term Liabilities	121.75	13.64	12.75	12.8	25.42
Total Liabilities	2,933	2,583	2,479	2,495	2,020

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	159.21	159.21	158.04	156.9	148.22
Additional Paid-In Capital	-	319.78	312.87	301.84	266.77
Retained Earnings	-	297.62	245.04	171.4	160.33
Comprehensive Income & Other	663.07	-2.45	4.09	7.75	10.95
Total Common Equity	822.27	774.16	720.04	637.89	586.27
Minority Interest	0.25	-0.12	-0.33	-0.87	-1.34
Shareholders' Equity	822.52	774.04	719.72	637.02	584.92
Total Liabilities & Equity	3,755	3,357	3,198	3,132	2,605

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	1,595	1,523	1,423	1,331	1,067
Net Cash (Debt)	-1,502	-1,419	-1,223	-1,256	-1,008
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-94.43	-89.51	-77.73	-80.06	-68.02
Filing Date Shares Outstanding	15.9	15.92	15.8	15.69	15.57
Total Common Shares Outstanding	15.9	15.92	15.8	15.69	14.82
Working Capital	130.06	153.72	311.04	188.22	189.26
Book Value Per Share	51.71	48.63	45.56	40.66	39.55
Tangible Book Value	649.78	726.1	669.28	586.45	545.89
Tangible Book Value Per Share	40.87	45.61	42.35	37.38	36.83
Land	-	172.71	148.93	148.93	79.1
Buildings	-	239.38	233.21	222.2	214.15
Machinery	-	763.63	671.8	613.08	558.05
Construction In Progress	-	27.86	4.72	-	16.12

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 30, 2026

Data Sources Report a data error